Ronnie Miller: "transformational products"- PGX-YBG 5X more potent
- First inhalable product
- Blew away industry gold standard in University of Alberta bioavailability study
- Potential first-in-class slow release formulations
- Potential Trojan Horse that can hijack macrophages for bioactive/drug delivery
- "...newly discovered mechanism of action through specific binding on white blood cells (macrophages) involved in the inflammation and fibrotic process." news release
- PGX-YBG/Fibrosis: "If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University."
- Thin films for fastest delivery to the blood
- PGX-YBG/C0Q10 Juvente - potential second-generation Aveeno
- PGX Technology increased surface area of sodium alginate 90 times compared to the conventionally dried sodium alginate. Also thermally stable.
- Research with Angiogenesis Foundation called a "home run"
- Professor Joerg Wischhusen from Julius-Maximilians-University Wuerzburg, who was involved in developing the AIM Biologicals technology that Aeterna Zentaris acquired, stated: "Based on preclinical data obtained by the University to date, the AIM Biologicals technology has the potential to be a breakthrough in the treatment of autoimmune-related diseases," including NMOSD.
- AEZS's growth hormone deficiency test is the first oral
and potentially the industry's first stand alone test.